Примери за използване на Given placebo на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Patients treated with sitagliptin had a modest increase in body weight compared to those given placebo.
This compares with 6% of those given placebo and with 70% of patients given ustekinumab.
Patients treated with sitagliptin had a modest increase in body weight(+1.1 kg)compared to those given placebo.
This compares with 4% of those given placebo and with 48% of patients given etanercept in 2 of the main studies.
Patients treated with Gilenya had around half the number of relapses compared with patients given placebo.
In the second study, patients given Yervoy with dacarbazine survived anaverage of 11 months, compared with 9 months in those given placebo plus dacarbazine, but about a third of the patients given Yervoy were unable to complete treatment due to side effects.
Patients given Xofigo lived on average for 14.9 months,compared with 11.3 months for those given placebo.
In addition, 7%(29 out of 403) of patients receiving Omidria experienced moderate-to-severe pain compared with 14%(57 out of 403)of patients given placebo, and 25%(104 out of 403) were painfree in the early period following surgery, compared with 17%(69 out of 403) of patients receiving placebo. .
Overall, 47% of infants given RotaTeq experienced an adverse reaction compared with 45.8% of infants given placebo.
The theory that antidepressants outperform placebo merely by means of side effects making the patient realizing that he orshe has not been given placebo, and herby enhancing the expectancy of improvement, may hence be rejected.
In the cancer studies, between 64 and 73% of patients who received Biopoin had an increase in haemoglobin of 2 g/dl compared with between 20 and26% of patients who were given placebo.
Also, 82% of patients given Taltz had clear ornearly clear skin after 12 weeks, compared with 4% of patients given placebo and 39% of patients given etanercept.
Approximately 52% of the patients treated with teduglutide experienced adverse reactions(versus 36% of the patients given placebo).
Among children aged between 9 and 16 years who had not had previous dengue infection,the risk of severe dengue disease if they later became infected with the virus was higher in people vaccinated compared with those given placebo(estimated at 2 additional cases per 1000 people vaccinated over 5 years).
Around 94% of the women given a year's treatment with Nerlynx lived for 1 further year after stopping Nerlynx without their cancer coming back versus 92% of those given placebo.
As dinutuximab is a recommended treatment for high-risk neuroblastoma,it would not be ethical to carry out a trial in which some patients were given placebo(a dummy treatment).
Fewer than 1 in 10 of the patients given Omidria had a pupil diameter below 6 mm(which makes surgery more difficult),whereas about 4 patients in 10 experienced this after being given placebo.
In a study involving 502 adults whose advanced melanoma had not been treated previously, patients treated with high-dose Yervoy and dacarbazine lived for 11 months on average, compared with 9 months for those given placebo(a dummy treatment) plus dacarbazine.
When only women with hormone-receptor positive cancer were considered,about 95% of those given Nerlynx lived another year without the cancer coming back versus 91% of those given placebo.
The review of Xofigo was carried out by EMA's Pharmacovigilance Risk Assessment Committee(PRAC) after data from a clinical study suggested that patients given Xofigo in combination with Zytiga and prednisone/prednisolone could be at risk of dying earlier andhad more fractures than patients given placebo(a dummy treatment) with Zytiga and prednisone/prednisolone.
Patients treated with Perjeta lived for 18.5 months without their disease getting worse,compared with 12.4 months for patients given placebo.
Overall, 47% of infants given RotaTeq experienced an adverse reaction compared with 45.8% of infants given placebo.
In cancer patients receiving chemotherapy,fewer patients treated with Nespo needed a blood transfusion compared with those given placebo.
In addition, most babies treated with Spinraza survived for longer andneeded breathing support later than those given placebo.
In the first study, disease activity decreased in 43% of patients treated with Benlysta,compared with 34% of patients who were given placebo.
In the second study, disease activity decreased in 58% of patients treated with Benlysta,compared with 44% of patients who were given placebo.
Flare-ups were seen in 32% of patients(151 out of 477)given Cinqaero compared with 50%(237 out of 476) of those given placebo.
With respect to pain, patients treated with Omidria reportedan average pain score of around 4, compared with around 9 for those given placebo.
Both studies showed that the pupil remained dilated during surgery in patients given Omidria(+0.1 mm),while it contracted in those given placebo(-0.5 mm).
Results showed patients given corticosteroids together with antibiotics were three times more likely to report total clearing up of pain after 24 hours than patients given placebo.